Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: SCH 717454 (19D12) is a fully human antibody directed against the insulin‐like growth factor 1 receptor (IGF‐1R), which is implicated in the growth and metastatic phenotype of a broad range of malignancies. The activity of SCH 717454 was evaluated against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP). Procedures: SCH 717454 was tested against the PPTP in vitro panel at concentrations ranging from 0.01 to 100 nM and was tested against the PPTP in vivo panel at a dose of 0.5 mg per mouse administered twice weekly for 4 weeks via intraperitoneal injection. Results: SCH 717454 was ineffective at retarding growth of cell lines in the in vitro panel. In vivo, SCH 717454 significantly increased event‐free survival in 20 of 35 (57%) solid tumor xenograft models with tumor regressions in one Ewing sarcoma model (complete response) and 2 osteosarcoma models (maintained complete responses). Using the time to event activity measure, SCH 717454 had intermediate (n = 9) or high (n = 1) activity against 31 evaluable solid tumor xenografts, including xenografts from the rhabdoid tumor, Ewing, rhabdomyosarcoma, glioblastoma, neuroblastoma, and osteosarcoma panels. SCH 717454 showed little activity against the 8 xenografts of the acute lymphoblastic leukemia panel. Conclusions: SCH 717454 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels. Further characterization of the molecular predictors of response and of the activity of combinations of SCH 717454 with other anticancer agents are anticipated. Pediatr Blood Cancer 2008;50:1190–1197. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
The pediatric preclinical testing program: Description of models and early testing results
Houghton, P. J., Morton, C. L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E. A., Zhang, W., Lock, R., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21078 · Cited by 480
Self-citation
Cited by
Common Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., Rose, P. S., Folpe, A. L., & Laack, N. N. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.01.015 · Cited by 298
Children's Oncology Group's 2013 blueprint for research: Bone tumors
Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226
“These clinical investigations in turn have been supported by promising preclinical data from the Pediatric Preclinical Testing Program (PPTP) among others [47,56,57].”
BackgroundSelf-citationSingh, P., Alex, J. M., & Bast, F. (2014) · Medical Oncology · doi:10.1007/s12032-013-0805-3 · Cited by 203
“In addition to inhibiting the in vitro proliferation of several cancer cell lines, this antibody proved fruitful in a various xenograft models, including ovarian (A2780), non-small cell lung cancer (H322), breast (MCF-7), and colon cancer (HT29) [141–144].”
BackgroundMolecular alterations as target for therapy in metastatic osteosarcoma: a review of literature
PosthumaDeBoer, J., Witlox, M. A., Kaspers, G. J. L., & van Royen, B. J. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9384-x · Cited by 194
“In vivo IGF-1R inhibition with monoclonal antibodies induced growth retardation in subcutaneous models of OS [ 79 , 84].”
BackgroundNeuroblastoma: Therapeutic strategies for a clinical enigma
Modak, S., & Cheung, N.-K. V. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.006 · Cited by 159
“IGF-1 receptor antagonists have been proven to have anti-NB activity in xenograft models.(142,143) Unlike sarcomas, it is not clear if IGF-1 receptor is overexpressed on NB cells.”
Background
Metadata
- Authors
- Kolb, E. A., Gorlick, R., Houghton, P. J., Morton, C. L., Lock, R., Carol, H., Reynolds, C. P., Maris, J. M., Keir, S. T., Billups, C. A., & Smith, M. A.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2008-02-07
- Volume
- 50
- Issue
- 6
- Pages
- 1190-1197
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- OpenAlex
- W2069622785
- Cited by
- 175
- References
- 3
- FWCI
- 16.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.